Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery (MAPSS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01765270
Recruitment Status : Terminated (The study was stopped due to poor enrollment.)
First Posted : January 10, 2013
Results First Posted : May 8, 2015
Last Update Posted : May 29, 2015
Sponsor:
Information provided by (Responsible Party):
Duke University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Individuals with type 2 diabetes mellitus (T2DM) are at increased risk for cardiovascular events (for example, heart attack) and the risk is related to one's overall control of blood glucose levels. In this study the investigators will measure the effects of saxagliptin, compared to placebo, before, during, and after coronary artery bypass graft (CABG) surgery. The investigators will use samples of the patients' blood and tissue to measure and evaluate indicators of the body's response to the treatment. This study is being done to evaluate the effect of saxagliptin on biomarkers of the heart to help us understand whether reducing or controlling a person's blood glucose levels during and after CABG surgery will produce better clinical outcomes (for example, better heart health).

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Mellitus Cardiovascular Disease Drug: Saxagliptin Drug: Placebo Phase 4

Detailed Description:
This study is a randomized, double-blind, placebo-controlled clinical trial to evaluate the effect of saxagliptin on cardiac biomarkers of myocardial necrosis, cardiac function, inflammation, and apoptosis in subjects with Type 2 diabetes mellitus (T2DM) undergoing CABG surgery (on pump, via a median sternotomy approach) as an integrated measure of the potential mechanistic effects of saxagliptin on prevention of cardiovascular (CV) outcomes. Approximately 74 subjects will be randomized and complete the study.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Official Title: Mechanistic Assessment of the Properties of Saxagliptin in Subjects Undergoing Coronary Artery Bypass Graft Surgery: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Study Start Date : March 2013
Actual Primary Completion Date : June 2014
Actual Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Saxagliptin

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Saxagliptin
Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
 Drug: Saxagliptin
one 5-mg saxagliptin tablet daily
Other Name: Onglyza
Placebo Comparator: Placebo
Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.
 Drug: Placebo
5mg placebo tablet daily


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Troponin I (TnI) Area Under the Curve (AUC) [ Time Frame: pre-CABG surgery (after 5 to 7 days of assigned treatment, predischarge or 5 days post-CABG surgery (Approximately 12 days) ]

Secondary Outcome Measures :
  1. High Sensitive Troponin-I (hsTnT) Area Under the Curve [ Time Frame: pre-CABG surgery (after 5 to 7 days of assigned treatment, predischarge or 5 days post-CABG surgery (Approximately 12 days) ]
  2. Creatine Kinase-Myocardial Bands (CK-MB) Area Under the Curve [ Time Frame: pre-CABG surgery (after 5 to 7 days of assigned treatment, predischarge or 5 days post-CABG surgery (Approximately 12 days) ]
  3. Number of Major Adverse Cardiac Events (MACE) [ Time Frame: Baseline to end of study (Approximately 35-37 days) ]
    Death, myocardial infarction (MI), or New congestive heart failure (CHF)

  4. Duration of Inotropic Support [ Time Frame: CABG surg until hosp discharge (Approximately 5 days) ]
  5. Number of Participants Who Had an Episode of Hypoglycemia [ Time Frame: baseline to end of study (Approximately 35-37 days) ]
  6. Number of Participants Who Required Intraaortic Balloon Pump (IABP) Support [ Time Frame: CABG to hospital discharge (Approximately 5 days) ]
  7. Need for Antiarrhythmic Therapy [ Time Frame: CABG surg to hospital discharge Approximately 5 days ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   45 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Known diagnosis of type 2 diabetes mellitus (T2DM) with glycosylated hemoglobin (HbA1c) between 6.5% and 10%, inclusive.

    • Stable doses of oral antihyperglycemic agents for at least 2 months
    • Stable dose of chronic insulin therapy for at least 2 months
    • HbA1c documented within 3 months before study enrollment
  • Planned first elective coronary artery bypass graft (CABG) surgery

Exclusion Criteria:

  • Elevated Creatine Kinase-Myocardial Bands (CK-MB) or troponin level above the 99th percentile at screening
  • Receiving incretin therapy or having received incretin therapy within the previous 2 months
  • Type 1 DM or a history of ketoacidosis
  • Women who are pregnant or breastfeeding
  • Known end-stage Kidney disease
  • Known sensitivity or intolerance to saxagliptin or dipeptidyl peptidase-4 (DPP-4) inhibitor
  • Clinically apparent liver disease
  • History of pancreatitis
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01765270


Locations
Layout table for location information
United States, Alabama
Cardiology, PC
Birmingham, Alabama, United States, 35211
Cardio-Thoracic Surgeons PC
Birmingham, Alabama, United States, 35243
Heart Center Research, LLC
Huntsville, Alabama, United States, 35801
United States, Arkansas
Sparks Regional Medical Center
Fort Smith, Arkansas, United States, 72901
Arkansas Cardiology, PA
Little Rock, Arkansas, United States, 72205
United States, California
Stanford University Medical Center
Palo Alto, California, United States, 94304
United States, Georgia
Emory University Hospital Midtown
Atlanta, Georgia, United States, 30308
United States, North Carolina
Duke University Medical Center (DUMC)
Durham, North Carolina, United States, 27710
United States, Virginia
Chippenham Medical Center
Richmond, Virginia, United States, 23225
United States, West Virginia
Charleston Area Medical Center (CAMC)
Charleston, West Virginia, United States, 25304
Sponsors and Collaborators
Duke University
Investigators
Layout table for investigator information
Principal Investigator: L. Kristin Newby, M.D., MHS Duke University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT01765270    
Other Study ID Numbers: Pro00041744
First Posted: January 10, 2013    Key Record Dates
Results First Posted: May 8, 2015
Last Update Posted: May 29, 2015
Last Verified: April 2015
Keywords provided by Duke University:
Diabetes
Diabetes Mellitus
Type 2 Diabetes
Cardiovascular Disease
Coronary Artery Bypass Surgery
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiovascular Diseases
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Saxagliptin
Incretins
 Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hypoglycemic Agents